CytoSorbents postpones Q4/FY2024 earnings to March 25 after controller's death; reaffirms prelim revenue

Cytosorbents Corp

Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).
Q4 product gross margin ~70%, vs 61% prior quarter and 72% Q4 2023.
Pro-forma cash balance Dec 31, 2024 ~$17.0M (incl. $7.3M net from rights offering/warrants); Q4 cash burn ~$2.5M.
DrugSorb-ATR marketing applications under substantive review with FDA and Health Canada; decisions expected in 2025.
Delay due to unexpected passing of VP and Corporate Controller James E. Cason, Jr.; earnings call rescheduled to March 25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.